Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: Effect on quality of life after liver transplantation

Riccardo Volpes, Patrizia Burra, Giacomo Germani, Matteo Angelo Manini, Lucio Caccamo, Paolo Strignano, Giorgia Rizza, Mariarosa Tamè, Antonio Daniele Pinna, Fulvio Calise, Carla Migliaccio, Paola Carrai, Paolo De Simone, Maria Filippa Valentini, Luigi Giovanni Lupo, Gabriella Cordone, Francesco Paolo Picciotto, Antonio Nicolucci

Research output: Contribution to journalArticlepeer-review


Background: Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or IM HBIG to the SC formulation. Methods: This multicentre, observational study involved adults who had undergone LT at least 1 year prior to study entry. Quality of life was evaluated using the ITaLi-Q questionnaire, assessing the impact of HBIG therapy on daily activities and patient satisfaction, and the SF-36 Health Survey. Patients completed the questionnaires prior to switching from IV or IM HBIG to SC HBIG and 6 months later. Results: Eighty-six patients were enrolled; before the switch, 68.6% were receiving IM HBIG and 31.4% IV HBIG. After 6 months, significant improvements in 7 of the 8 ITaLi-Q domains were found, particularly side effects, need for support to adhere to the therapy and satisfaction with the HBIG therapy. Significant improvements in several SF-36 domains were documented, including physical functioning, physical and emotional role limitations, pain, social functioning, physical and mental summary scores. Conclusions: The SC route of administration reduces side effects and their interference with daily life, ameliorates negative feelings, and increases patient autonomy.
Original languageEnglish
JournalHealth and Quality of Life Outcomes
Issue number1
Publication statusPublished - Apr 10 2020


  • Acceptability of treatment
  • Patient autonomy
  • Questionnaire
  • Satisfaction
  • Side effects


Dive into the research topics of 'Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: Effect on quality of life after liver transplantation'. Together they form a unique fingerprint.

Cite this